Arrowhead Pharmaceuticals (ARWR) Osake Kurssi

Arrowhead Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Arrowhead Pharmaceuticals Inc in the market are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Dicerna Pharmaceuticals.

Arrowhead Pharmaceuticals Inc is a leading biopharmaceutical company with a rich history and background. Founded in 1989, Arrowhead Pharmaceuticals has focused on developing innovative RNA interference (RNAi) therapies to treat various diseases. Over the years, the company has made significant advancements in the field of genetic medicine, utilizing its proprietary Targeted RNAi Molecule (TRiM™) platform. Arrowhead Pharmaceuticals has a robust pipeline of therapeutic candidates targeting liver, respiratory, and cardiovascular diseases, among others. With a strong commitment to research and development, the company aims to revolutionize patient care by providing effective and personalized RNAi-based therapies. Arrowhead Pharmaceuticals Inc continues to make strides in the biopharmaceutical industry, offering hope for patients worldwide.

Arrowhead Pharmaceuticals Inc has achieved several significant milestones. In recent years, the company has successfully completed clinical trials for its RNA interference (RNAi) therapies, demonstrating their potential in treating various diseases. Arrowhead Pharmaceuticals Inc has also entered into collaborations with major pharmaceutical companies to further develop and commercialize its RNAi therapeutics. Additionally, the company has received regulatory approvals for its investigational drugs, paving the way for potential market launches. Furthermore, Arrowhead Pharmaceuticals Inc has consistently shown promising results in preclinical and early-stage trials, highlighting the potential efficacy and safety of its innovative therapeutic approaches.

Arrowhead Pharmaceuticals Inc is primarily present in the United States.

Arrowhead Pharmaceuticals Inc represents a values-driven corporate philosophy focused on innovation, collaboration, and excellence. The company is committed to advancing RNAi therapeutics to transform the lives of patients with severe and life-threatening diseases. Arrowhead Pharmaceuticals Inc prioritizes patient-centricity, scientific integrity, and ethical practices. By leveraging its deep expertise in RNAi-based therapeutics, the company strives to deliver breakthrough treatments and improve patient outcomes. With a strong emphasis on R&D, Arrowhead Pharmaceuticals Inc demonstrates its dedication to cutting-edge research and development of innovative therapies that hold the potential to address unmet medical needs.

Analyytikot asettavat tällä hetkellä Arrowhead Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 105,17 USD (mediaani: 117,50 USD), mikä merkitsee +77,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.

Arrowhead Pharmaceuticals Analyytikkojen kursstavoitteet 2026

20 analyytikkoa arvioi tällä hetkellä Arrowhead Pharmaceuticals-osaketta: 19 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Arrowhead Pharmaceuticals-yhtiöltä 461,89 M USD liikevaihtoa ja −3,38 USD osakekohtaista tulosta.

Arrowhead Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Arrowhead Pharmaceuticals-osake noteerataan hintaan 52,83 EUR (59,13 USD).

Arrowhead Pharmaceuticals-osake (ARWR) on listattuna 7 pörssissä, muun muassa: NASDAQ (ARWR), London (0HI3.L), SIX (Zürich) (HDP1.SW), Frankfurt (HDP1.F), München (HDP1.MU), Düsseldorf (HDP1.DU).

Arrowhead Pharmaceuticals Inc is a biopharmaceutical company focused on the development of RNA interference (RNAi) and small molecule drugs. The company was founded in 2000 and is headquartered in Pasadena, California. Arrowhead Pharmaceuticals' business model includes several divisions. The company focuses on developing RNAi therapeutics for various diseases such as hepatitis B, alpha-1 antitrypsin deficiency, and cardio-metabolic disorders. RNAi is a process of highly specific silencing of certain genes involved in the cause of certain diseases. The first division of Arrowhead Pharmaceuticals is drug development. The company is developing RNAi therapeutics for the treatment of liver diseases, including hepatitis B and alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals is also developing therapeutics for cardiovascular diseases such as diabetes and obesity. The second division of Arrowhead Pharmaceuticals is collaboration with other companies. Arrowhead has made several agreements with other pharmaceutical companies. These partnerships allow Arrowhead to leverage its technology platform and products in combination with the capabilities and resources of its partners to develop better products and solutions. The third division of Arrowhead Pharmaceuticals is intellectual property (IP) management. Arrowhead has a strong IP portfolio and holds patents that protect its technology and research. The company continuously develops new technologies and improves its products to strengthen its position in the market. Arrowhead Pharmaceuticals completed its acquisition of Amgen's RNA Interference (RNAi) business on September 3, 2020, to expand and diversify Arrowhead Pharmaceuticals' RNAi portfolio by adding the talents and resources of Amgen. As part of the transaction, Arrowhead and Amgen entered into a strategic collaboration agreement in the field of RNA interference product delivery. Arrowhead Pharmaceuticals has several products on the market, including the hepatitis B drug ARO-HBV, which is in Phase 2 clinical trials and has the potential to contribute to the cure of chronic hepatitis B. The drug has been designated as an "Orphan Drug" by the US Food and Drug Administration (FDA), providing a significant opportunity to address the need for this rare disease. The company has also developed an RNAi therapeutic called ARO-AAT for the treatment of alpha-1 antitrypsin deficiency. The drug is in Phase 2 of development and potentially has the potential to increase the number of targeted patients in the coming years. Overall, Arrowhead Pharmaceuticals has a strong business model as the company focuses on a proven and scientifically based technology platform to develop effective therapeutic solutions for common and rare diseases. By partnering with other pharmaceutical companies, Arrowhead can further improve its technology and products and expand its capabilities. By managing its intellectual property, Arrowhead also ensures that its products and solutions are protected from imitation.

odotettu liikevaihto Arrowhead Pharmaceuticals on 461,89 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Arrowhead Pharmaceuticals on −474,95 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Arrowhead Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä −17,52. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Arrowhead Pharmaceuticals-osakkeen arvostusta.

Arrowhead Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 18,01. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Arrowhead Pharmaceuticals-osakkeen arvostuskennuslukuna.

Arrowhead Pharmaceuticals:n Eulpool-laatuscore on 5/10.

Arrowhead Pharmaceuticals:n ISIN on US04280A1007. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Arrowhead Pharmaceuticals:n WKN on A2AGYB. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Arrowhead Pharmaceuticals:n ticker on ARWR. Tämä pörssinoteeraus käytetään Arrowhead Pharmaceuticals-osakkeiden kauppaan pörssissä.